309 related articles for article (PubMed ID: 11093687)
1. New insights on the pathogenesis of hypercalcemia in primary hyperparathyroidism.
Yonemura K; Suzuki H; Fujigaki Y; Hishida A
Am J Med Sci; 2000 Nov; 320(5):334-6. PubMed ID: 11093687
[TBL] [Abstract][Full Text] [Related]
2. Primary hyperparathyroidism and severe hypercalcemia with low circulating 1,25-dihydroxyvitamin D.
Shaker JL; Krawczyk KW; Findling JW
J Clin Endocrinol Metab; 1990 Nov; 71(5):1305-9. PubMed ID: 2229288
[TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
4. Normocalcemic primary hyperparathyroidism: resistance to PTH effect on tubular reabsorption of calcium.
Gardin JP; Paillard M
Miner Electrolyte Metab; 1984; 10(5):301-8. PubMed ID: 6493158
[TBL] [Abstract][Full Text] [Related]
5. Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers.
Horwitz MJ; Tedesco MB; Sereika SM; Hollis BW; Garcia-Ocaña A; Stewart AF
J Clin Endocrinol Metab; 2003 Apr; 88(4):1603-9. PubMed ID: 12679445
[TBL] [Abstract][Full Text] [Related]
6. Is there a role for parathyroid hormone in humoral hypercalcemia of malignancy?
Stewart AF
Miner Electrolyte Metab; 1982; 8(3-4):215-26. PubMed ID: 6300632
[No Abstract] [Full Text] [Related]
7. Comparison of intestinal calcium absorption and circulating 1,25-dihydroxyvitamin D levels in malignancy-associated hypercalcaemia and primary hyperparathyroidism.
Ralston SH; Cowan RA; Gardner MD; Fraser WD; Marshall E; Boyle IT
Clin Endocrinol (Oxf); 1987 Mar; 26(3):281-91. PubMed ID: 3652475
[TBL] [Abstract][Full Text] [Related]
8. A patient with primary hyperparathyroidism associated with osteomalacia: markedly increased serum levels of intact PTH and 1,25-dihydroxyvitamin D with normo- and hypercalcemia.
Takemia T; Sato K; Miyata M; Imaki T; Shibasaki T; Tsushima T; Demura H; Tanaka R; Obara T; Oguchi S
Endocr J; 1993 Feb; 40(1):121-6. PubMed ID: 7951485
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of 1,25(OH)2D production by hypercalcemia in osteitis fibrosa cystica: influence on parathyroid hormone secretion and hungry bone disease.
Brossard JH; Garon J; Lepage R; Gascon-Barré M; D'Amour P
Bone Miner; 1993 Oct; 23(1):15-26. PubMed ID: 8274876
[TBL] [Abstract][Full Text] [Related]
10. Circulating parathyroid hormone activity: familial hypocalciuric hypercalcemia versus typical primary hyperparathyroidism.
Marx SJ; Spiegel AM; Brown EM; Windeck R; Gardner DG; Downs RW; Attie M; Aurbach GD
J Clin Endocrinol Metab; 1978 Dec; 47(6):1190-7. PubMed ID: 233692
[TBL] [Abstract][Full Text] [Related]
11. Lack of effect of 24,25-dihydroxyvitamin D3 administration on parameters of calcium metabolism.
Harvey JA; Zerwekh JE; Sakhaee K; Pak CY
J Clin Endocrinol Metab; 1989 Aug; 69(2):467-9. PubMed ID: 2787802
[TBL] [Abstract][Full Text] [Related]
12. Hypercalcemia with low-normal serum intact PTH: a novel presentation of primary hyperparathyroidism.
Hollenberg AN; Arnold A
Am J Med; 1991 Nov; 91(5):547-8. PubMed ID: 1951417
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of bone resorption and renal tubular reabsorption of calcium and phosphate in malignant and nonmalignant hypercalcemia.
Buchs B; Rizzoli R; Bonjour JP
Bone; 1991; 12(1):47-56. PubMed ID: 2054236
[TBL] [Abstract][Full Text] [Related]
14. [Primary hyperparathyroidism. Mechanisms of hypercalcemia].
Baglin A; Junien C; Prinseau J
Presse Med; 1991 Apr; 20(15):701-5. PubMed ID: 1675465
[TBL] [Abstract][Full Text] [Related]
15. Increased prevalence of primary hyperparathyroidism in treated breast cancer.
Fierabracci P; Pinchera A; Miccoli P; Conte PF; Vignali E; Zaccagnini M; Marcocci C; Giani C
J Endocrinol Invest; 2001 May; 24(5):315-20. PubMed ID: 11407650
[TBL] [Abstract][Full Text] [Related]
16. The hypercalciurias. Causes, parathyroid functions, and diagnostic criteria.
Pak CY; Oata M; Lawrence EC; Snyder W
J Clin Invest; 1974 Aug; 54(2):387-400. PubMed ID: 4367891
[TBL] [Abstract][Full Text] [Related]
17. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
[TBL] [Abstract][Full Text] [Related]
18. [Hormonal interactions of parathormone and calcium metabolism].
Kovács L
Orv Hetil; 2003 Jan; 144(1):3-12. PubMed ID: 12635347
[TBL] [Abstract][Full Text] [Related]
19. [Should the parathyroid function be evaluated in a patient with calcium kidney stones? If so, when and why?].
Gardin JP; Houillier P; Borensztein P; Paillard M
Nephrologie; 1991; 12(2):71-7. PubMed ID: 1944759
[TBL] [Abstract][Full Text] [Related]
20. 1,25-dihydroxyvitamin D3 as well as its analogue OCT lower blood calcium through inhibition of bone resorption in hypercalcemic rats with continuous parathyroid hormone-related peptide infusion.
Endo K; Katsumata K; Hirata M; Masaki T; Kubodera N; Nakamura T; Ikeda K; Ogata E
J Bone Miner Res; 2000 Jan; 15(1):175-81. PubMed ID: 10646127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
